From Diarrhea to Obesity in Prohormone Convertase 1/3 Deficiency: Age-dependent Clinical, Pathologic, and Enteroendocrine Characteristics
Overview
Authors
Affiliations
Goals: The aim of this report is to delineate the clinical, pathologic, and enteroendocrine (EE) features of prohormone convertase 1/3 (PC1/3) deficiency in children.
Background: Prohormone convertases play a pivotal role in the activation of biologically inactive hormones. Congenital defects in the EE axis, such as PC1/3 deficiency, have been rarely reported and their pathophysiological mechanisms are largely unknown.
Study: EE function and pathology was evaluated in 4 males (1, 2, 7, and 10 y old) from 2 families with PC1/3 deficiency at a university children's hospital. Clinical course, pathology analysis including immunohistochemistry for PC1/3, PC2, and glucagon-like peptide 1 (GLP-1) and electron microscopy, as well as EE function tests (GLP-1, GLP-2, oral glucose tolerance test) were performed.
Results: All (n=4) suffered from congenital severe diarrhea associated with malabsorption. The diarrhea improved during the first year of life and hyperphagia with excessive weight gain (BMI>97th percentile) became the predominant phenotype at an older age. Analysis of the enteroendocrine axis revealed high proinsulin levels (57 to 1116 pmol/L) in all patients, low serum GLP-2 levels, and impaired insulin and GLP-1 secretion after an oral glucose tolerance test at a young age, with improvement in 1 older child tested. Electron microscopy showed normal ultrastructure of enterocytes and EE cells. Immunohistochemistry revealed normal expression of chromogranin A, a marker of EE cells but markedly reduced immunostaining for PC1/3 and PC2 in all patients.
Conclusions: PC1/3 deficiency is associated with an age dependent, variable clinical phenotype caused by severe abnormalities in intestinal and EE functions. Serum level of proinsulin can be used as an effective screening tool.
Enteroendocrine cell regulation of the gut-brain axis.
Barton J, Londregan A, Alexander T, Entezari A, Covarrubias M, Waldman S Front Neurosci. 2023; 17:1272955.
PMID: 38027512 PMC: 10662325. DOI: 10.3389/fnins.2023.1272955.
Genetics: A Starting Point for the Prevention and the Treatment of Obesity.
Novelli G, Cassadonte C, Sbraccia P, Biancolella M Nutrients. 2023; 15(12).
PMID: 37375686 PMC: 10305006. DOI: 10.3390/nu15122782.
Modulation of PC1/3 activity by a rare double-site homozygous mutation.
Ni Y, Chen X, Sun Y, Pan J, Tang C, Yuan T Front Pediatr. 2022; 10:1026707.
PMID: 36389395 PMC: 9659753. DOI: 10.3389/fped.2022.1026707.
Van Dijck E, Beckers S, Diels S, Huybrechts T, Verrijken A, Van Hoorenbeeck K Genes (Basel). 2022; 13(10).
PMID: 36292633 PMC: 9601648. DOI: 10.3390/genes13101746.
The G209R mutant mouse as a model for human PCSK1 polyendocrinopathy.
Shakya M, Gahlot S, Martin N, Arunagiri A, Martin M, Arvan P Endocrinology. 2022; .
PMID: 35245347 PMC: 9044177. DOI: 10.1210/endocr/bqac024.